Cargando…

Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype

Triple negative breast cancer (TNBC) represents the most aggressive breast tumor, showing a high intrinsic variability in terms of both histopathological features and response to therapies. Blocking the Akt signaling pathway is a well-studied approach in the treatment of aggressive breast tumors. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grassilli, Silvia, Brugnoli, Federica, Cairo, Stefano, Bianchi, Nicoletta, Judde, Jean-Gabriel, Bertagnolo, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224635/ https://www.ncbi.nlm.nih.gov/pubmed/35743776 http://dx.doi.org/10.3390/jpm12060993

Ejemplares similares

Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic Cancer
por: Grassilli, Silvia, et al.
Publicado: (2020)

Mir-29b in Breast Cancer: A Promising Target for Therapeutic Approaches
por: Grassilli, Silvia, et al.
Publicado: (2022)

Vav1 is necessary for PU.1 mediated upmodulation of miR‐29b in acute myeloid leukaemia‐derived cells
por: Vezzali, Federica, et al.
Publicado: (2018)

Vav1 downmodulates Akt in different breast cancer subtypes: a new promising chance to improve breast cancer outcome
por: Grassilli, Silvia, et al.
Publicado: (2018)

Vav1 Sustains the In Vitro Differentiation of Normal and Tumor Precursors to Insulin Producing Cells Induced by all-Trans Retinoic Acid (ATRA)
por: Brugnoli, Federica, et al.
Publicado: (2020)

In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133(high) to CD133(low) phenotype and reduces the CD133-related invasiveness
por: Brugnoli, Federica, et al.
Publicado: (2013)

Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC
por: Brugnoli, Federica, et al.
Publicado: (2017)

High nuclear level of Vav1 is a positive prognostic factor in early invasive breast tumors: a role in modulating genes related to the efficiency of metastatic process
por: Grassilli, Silvia, et al.
Publicado: (2014)

CD133 in Breast Cancer Cells: More than a Stem Cell Marker
por: Brugnoli, Federica, et al.
Publicado: (2019)

Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells
por: Al-Qassab, Yasamin, et al.
Publicado: (2018)

The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2
por: Bianchi, Nicoletta, et al.
Publicado: (2021)

The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma
por: Crudele, Francesca, et al.
Publicado: (2021)

A Multidisciplinary Approach Establishes a Link between Transglutaminase 2 and the Kv10.1 Voltage-Dependent K(+) Channel in Breast Cancer
por: Canella, Rita, et al.
Publicado: (2022)

UC.183, UC.110, and UC.84 Ultra-Conserved RNAs Are Mutually Exclusive with miR-221 and Are Engaged in the Cell Cycle Circuitry in Breast Cancer Cell Lines
por: Corrà, Fabio, et al.
Publicado: (2021)

Ectopic expression of PLC‐β2 in non‐invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR‐146a
por: Bertagnolo, Valeria, et al.
Publicado: (2019)

The Effect of Different Storage Conditions on Phytochemical Composition, Shelf-Life, and Bioactive Compounds of Voghiera Garlic PDO
por: Tedeschi, Paola, et al.
Publicado: (2023)

Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells
por: Volinia, Stefano, et al.
Publicado: (2018)

Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors
por: Perretta-Tejedor, Nuria, et al.
Publicado: (2017)

Corrigendum: Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors
por: Perretta-Tejedor, Nuria, et al.
Publicado: (2018)

VAV2 and VAV3 as Candidate Disease Genes for Spontaneous Glaucoma in Mice and Humans
por: Fujikawa, Keiko, et al.
Publicado: (2010)

Vav2 is required for cell spreading
por: Marignani, Paola A., et al.
Publicado: (2001)

Vav Proteins' Role in Skin Cancer
por: Mejia, Robin
Publicado: (2013)

The Rho guanosine nucleotide exchange factors Vav2 and Vav3 modulate epidermal stem cell function
por: Lorenzo-Martín, L. Francisco, et al.
Publicado: (2022)

MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3
por: Teng, Yue, et al.
Publicado: (2015)

Vav Regulates Peptide-specific Apoptosis in Thymocytes
por: Kong, Young-Yun, et al.
Publicado: (1998)

The Vav GEF Family: An Evolutionary and Functional Perspective
por: Rodríguez-Fdez, Sonia, et al.
Publicado: (2019)

The Rho Exchange Factors Vav2 and Vav3 Favor Skin Tumor Initiation and Promotion by Engaging Extracellular Signaling Loops
por: Menacho-Márquez, Mauricio, et al.
Publicado: (2013)

Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer
por: Jurj, Ancuta, et al.
Publicado: (2023)

Vav1 Is a Component of Transcriptionally Active Complexes
por: Houlard, Martin, et al.
Publicado: (2002)

Mechanism and function of Vav1 localisation in TCR signalling
por: Ksionda, Olga, et al.
Publicado: (2012)

VAV1 Gene Polymorphisms in Patients with Rheumatoid Arthritis
por: Pawlik, Andrzej, et al.
Publicado: (2020)

Vav1 Promotes B-Cell Lymphoma Development
por: Shalom, Batel, et al.
Publicado: (2022)

Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway
por: Liu, Mian, et al.
Publicado: (2022)

LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma
por: Xiao, Ying, et al.
Publicado: (2020)

VAV3 mediates resistance to breast cancer endocrine therapy
por: Aguilar, Helena, et al.
Publicado: (2014)

Vav family exchange factors: an integrated regulatory and functional view
por: Bustelo, Xosé R
Publicado: (2014)

Activation of RHOA–VAV1 signaling in angioimmunoblastic T-cell lymphoma
por: Fujisawa, M, et al.
Publicado: (2018)

Evaluation of Vav3.1 as prognostic marker in endometrial cancer
por: Boesch, Maximilian, et al.
Publicado: (2018)

Phosphatidylinositol Monophosphates Regulate Optimal Vav1 Signaling Output
por: Rodríguez-Fdez, Sonia, et al.
Publicado: (2019)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ikafs3ok6j9hucls0hnip0t1vt